Envafolimab
As of the edition of 20 October 2026, Envafolimab is an antibody: stopped in 2026; acts on CD274.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Antibody
- Registered trials
- 86, 1 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Urinary and reproductive; Pregnancy and women's health; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Envafolimab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD274 | Programmed cell death 1 ligand 1 | Q9NZQ7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 0 | 2 | 0 |
| Phase 1 | 4 | 3 | 1 | 0 |
| Phase 2 | 72 | 5 | 32 | 1 |
| Phase 3 | 3 | 1 | 2 | 0 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 86 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| 3D Medicines | Lead sponsor of trials | 2017 to now |
| Ascletis Pharmaceuticals | Lead sponsor of trials | 2020 to now |
| Tracon Pharmaceuticals | Lead sponsor of trials | 2020 to now |
| Chipscreen Biosciences | Lead sponsor of trials | 2021 to now |
| Jiangsu Simcere Pharmaceutical | Lead sponsor of trials | 2021 to now |
| Kangabio | Lead sponsor of trials | 2024 to now |